Conclusions
•
Olaparib is the first PARPi approved for the BRCAmut ovarian cancer
patients:
–
EMA: as maintence therapy
–
FDA: as monotherapy in heavily pretreated patients
•
A few patients are long responders(olaparib more than 5 years after
initiation of treatment):
–
How to identify them?
–
Are these patients potentially cured?
•
Olaparib + Cediranib: a promising regimen. Waiting for randomized
clinical trials results.
•
Results from SOLO-1 may change the first line treatment in BRCAmut
patients
